← FDA DRUG APPROVALS
FDA ANDA · ANDA207457
SUMATRIPTAN AND NAPROXEN SODIUM
Sponsor: AUROBINDO PHARMA LTD
APPLICATION
ANDA207457
TYPE
ANDA
ORIGINAL APPROVAL
2018-02-15
LATEST ACTION
2020-06-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
SUMATRIPTAN AND NAPROXEN SODIUMPrescription
NAPROXEN SODIUM 500MG, SUMATRIPTAN SUCCINATE EQ 85MG BASE · TABLET · ORAL
Approval history
2020-06-24Labeling · Supplement 6 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.